Hosted on MSN1mon
Rodman & Renshaw sets Talphera stock Buy rating, $4 target
for a Prior Approval Supplement (PAS) to amend its NEPHRO CRRT clinical study. The review aims to reduce the number of patients required for the study, which evaluates Niyad™, an anticoagulant ...
Medscape3d
Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis
The medication costs of vitamin D therapy differed with respect ... costs of 375 (Eins Alpha ®, Bocatriol ®, Calcitriol-Nephro ® and Decostriol ®), intravenous treatment was associated ...